Your Host: Institute of Tumor Biology
University Medical Center Hamburg-Eppendorf

The ITB was founded in 2002 to bridge between basic research and the clinic. Translational research conducted in our laboratory aims at a better understanding of the molecular mechanisms underlying cancer development and progression, improved cancer diagnostics and also treatment of cancer patients, with a particular emphasis on so called ‘targeted therapies’. Research at ITB contributed significantly to an improvement of cancer diagnostics of a variety of cancers by, for example, the development of blood diagnostic tests (‘liquid biopsy’) and by identification and characterization of novel biomarkers for certain cancer types.

With the start of 2020, the European Liquid Biopsy Society (ELBS) was established by the initiative of Prof. Klaus Pantel, physician and tumor biologist at the University hospital Hamburg-Eppendorf (UKE). Academic partner institutions and partners from industry (SME as well as large diagnostic and pharma companies) want to jointly promote research around liquid biopsy and its use in clinical practice. ELBS is open to attract new partners and will be a hub for liquid biopsy research in Europe with the key goal to translate liquid biopsy assays into clinical practice for the benefit of patients.